3213-16-9 Usage
Uses
Used in Pharmaceutical Industry:
2-(diethylamino)-N-(3,4-dimethyl-phenyl)acetamide is utilized as an analgesic for the management of mild to moderate pain. Its ability to reduce pain is attributed to its action on the cyclooxygenase enzyme, thereby decreasing prostaglandin production which is linked to pain sensation.
2-(diethylamino)-N-(3,4-dimethyl-phenyl)acetamide is also used as an antipyretic agent to treat fever. By inhibiting the same enzyme involved in prostaglandin synthesis, it helps in lowering elevated body temperatures associated with fever.
Additionally, it serves as an anti-inflammatory agent, addressing conditions characterized by inflammation due to its impact on prostaglandin levels.
Furthermore, 2-(diethylamino)-N-(3,4-dimethyl-phenyl)acetamide is employed as a mild sedative, providing calming effects that can be beneficial in certain therapeutic contexts.
Check Digit Verification of cas no
The CAS Registry Mumber 3213-16-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,2,1 and 3 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 3213-16:
(6*3)+(5*2)+(4*1)+(3*3)+(2*1)+(1*6)=49
49 % 10 = 9
So 3213-16-9 is a valid CAS Registry Number.
3213-16-9Relevant academic research and scientific papers
Synthesis and antispasmodic activity of lidocaine derivatives endowed with reduced local anesthetic action
Costa, Jorge C.S.,Neves, Josiane S.,de Souza, Marcus V.N.,Siqueira, Rodrigo A.,Romeiro, Nelilma C.,Boechat, Nubia,Silva, Patricia M.R.e,Martins, Marco A.
, p. 1162 - 1166 (2008/09/20)
The present structure-activity relationship (SAR) study focused on chemical modifications of the structure of the local anesthetic lidocaine, and indicated analogues having reduced anesthetic potency, but with superior potency relative to the prototype in preventing anaphylactic or histamine-evoked ileum contraction. From the SAR analysis, 2-(diethylamino)-N-(trifluoromethyl-phenyl) and 2-(diethylamino)-N-(dimethyl-phenyl) acetamides were selected as the most promising compounds. New insights into the applicability of non-anesthetic lidocaine derivatives as templates in drug discovery for allergic syndromes are provided.
